1 / 42

Recent Developments in the World of Diabetes

July 22, 2009 . Recent Developments in the World of Diabetes. Ali A. Rizvi, MD Department of Medicine Division of Endocrinology, Diabetes, and Metabolism University of South Carolina School of Medicine.

holt
Download Presentation

Recent Developments in the World of Diabetes

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. July 22, 2009 Recent Developments in the World of Diabetes Ali A. Rizvi, MD Department of Medicine Division of Endocrinology, Diabetes, and Metabolism University of South Carolina School of Medicine

  2. Evolution of Diabetes Technology and Treatments: Timeline Bewildering and empowering for clinicians and patients Insulin Pumps • Glucose Sensors • Insulin Analogs • New Oral agents Glucose Meters • REAL- Time monitoring • Incretin-based Therapies • Inhaled Insulin Urine Test Strips Urine Tasting Insulin Injections Artificial Pancreas: “Closing the Loop” 1900s 1922 1776 1977 1978 1999 The Diabetes and Obesity Epidemic

  3. The epidemic of….Diabetes, “Pre-diabetes” and the Metabolic SyndromeWhat lies beneath • Impaired fasting glucose: 100 – 125 mg/dl • Impaired glucose tolerance: 2-hour OGTT value of 140-199 mg/dl • Insulin resistance and Metabolic Syndrome • Progression to diabetes halted with lifestyle changes (DPP study)

  4. We will review…Know current and evolving methods of glucose testing and monitoringBe familiar with results of recent studies regarding diabetes and its complicationsApply an evidence-based approach to the treatment of diabetes in the office and hospital setting Discuss thorny questions (debates) – controversial or unresolved

  5. Meter Downloads and Data Management Systems Computer software and Data management systems for office download of data for print-out and pattern analysis Meters with Built-in Data Analysis

  6. The Sugar DebatesValue of SMBG for patients with diabetesFarmer et al, BMJ 2007 • Established in insulin-treated patients • Not proven in patients who are on lifestyle management or oral agents and reasonably well-controlled • Most useful if used as feedback to make meaningful changes in therapy: review, respond, and use the data for improvement “If you cannot measure it, you cannot improve it” - Lord Kelvin

  7. Minimally Invasive, Continuous Glucose Monitoring (CGM) Professional CGM for Physician Use: very frequent glucose readings – every 5 minutes, or 288 readings a day Worn for 3 days, with a tiny sensor inserted beneath the skin Downloaded and analyzed by the physician in the office

  8. Pre-Conception Planning with CGM 31 yr old type 2 DM on multiple daily insulin injections, switched to pump 3 months prior to pregnancy, 2 months after pump A1c 6.7, 2 months after CGM A1c 5.7% U.K. Study: Murphy et al. Changes in the Glycemic Profiles of Women with Type 1 (140 profiles) and Type 2 Diabetes (40 profiles) during pregnancy. Diabetes Care Nov 2007 (time spent in hyper- and hypoglycemia and risk of nocturnal hypoglycemia)

  9. Real-Time “Personal” CGM for Patient Use A System of Continuous Glucose Monitoring and “Sensor-Augmented”Pump • The MiniMed Paradigm REAL-Time System with MiniLink Sensor • A tiny glucose sensor C that is worn for up to three days at a time • Easily inserted using an automatic insertion device • Glucose sensor data is sent continuously to a MiniLink™ REAL- Time Transmitter D, • Transmitter sends the glucose data to the insulin pump A • REAL-Time Readings, Alarms, Trend Arrows, Trend Graphs

  10. Reports from the web-based CareLink™ Personal Software

  11. Personal CGMs

  12. Continuous Glucose Monitoring and Intensive Treatment of Type 1 DiabetesNew Engl J Med October 2, 2008 • 322 patients, majority pump users followed for 26 weeks • Better control in adults (>24 yrs) A1c decrease -0.53% • Improvement related to duration of use • No difference in rates of severe hypoglycemia • Identify barriers to effectiveness of CGM in children and adolescents

  13. A1c Derived Average Glucose (ADAG) Study and eAGTranslating the A1c assay into estimated average glucose Diabetes Care, August 2008 • Increased accuracy of HbA1c in reflecting the true average glycemia • Results reported as A1c-derived average glucose (in mmol and mg/dl) or “estimated average glucose”, eAG

  14. The sugar debates: A1c for the diagnosis of diabetesInternational Expert Committee Report on the Role of A1c Testing to Diagnose Diabetes: Joint Recommendations from IDF, EASD, and ADAADA Scientific Sessions, New Orleans, June 2009 Advantages of A1c vs. FPG or OGTT: better indicator of overall glycemic exposure good for predicting complications less variability, unaffected by outside factors like stress not a timed test, requires no fasting; more convenient ≥6.5% seems to be a reasonable cut-point to avoid over-diagnosis. An A1c 6 – 6.5% indicates high risk for developing diabetes

  15. Genetics of type 2 diabetes: the advent of genome-wide association scans (GWAS) • Two dozen genetic susceptibility variants (“SNPs”) identified since February 2007 • Some may have monogenic potential • Explains only 5-10% of the genetic basis. Genotype information does not improve upon traditional diabetes predication tools • May predict risk of complications, and response to commonly-prescribed diabetes medication classes (genetic profiling and personalized medicine)

  16. Insulin Analogues compared with Human Insulins: Action Profiles 2 3 4 5 6 7 8 9 12 13 14 15 16 17 18 19 20 21 22 23 24 0 1 10 11 RAPID-ACTING: Aspart, glulisine,lispro 4–5 hours Plasma insulin levels Regular 6–8 hours NPH 12–20 hours LONG-ACTING: Glargine 24 hours Detemir 20 hours Hours

  17. Multiple Daily Insulin Injections: Vial and Syringe Insulin Delivery Devices Insulin Pens:The Pen is Mightier than the Syringe… A different method of insulin delivery:Insulin Pumps

  18. Basal-Bolus Insulin Treatmentwith Insulin Analogues 0600 1800 0800 0600 1200 2400 Lispro, glulisine, or aspart U/mL 100 Glargine or Detemir B L D 80 60 Normal pattern 40 20 Time of day B=breakfast; L=lunch; D=dinner

  19. Analog Basal-BolusPros and Cons… • A “physiologic” concept of insulin administration that m • Better “designer” insulins that mimic normal pancreatic release • Less hypoglycemia, esp. at night • Improved methods to deliver them • Expensive! • Cancer risk with glargine? Diabetologia June 2009

  20. Premixed Insulins Human Premixes Humulin 70/30, Novolin 70/30 Analog Premixes these are‘biphasic’ insulin formulations Humalog Mix 75/25, Novolog Mix 70/30 Humalog Mix 50/50, Novolog Mix 50/50 • Convenient (type 2 diabetes) • Lack flexibility of ratio and dosing

  21. “Most patients with type 2 diabetes who fail to achieve adequate glucose control with oral agents are likely to need combination insulin therapy in the long run”Final Results: IDF, Montreal, October 2009 The Sugar DebatesHow best to initiate insulin in type 2 diabetes? New Engl J Med, October 2007 The ongoing “4-T” study

  22. Diabetes is a Multi-System Disorder: “The Incretin Effect” Liver Pancreas GLP-1 and other gut hormones released in response to food: “entero-insular axis” This ability is reduced or lost in type 2 diabetes Suppressed post-prandial glucagon Decreased Glucose Output Enhanced Insulin secretion GLP-1 release Food Slowed gastric emptying Increased Satiety

  23. Heloderma Suspectum “Incretin-mimetics” – exenatide (Byetta) • Synthetic mimetic and agonist of GLP-1 • Approved in combination with oral agents • Weight loss or weight-neutral • May cause nausea and vomiting • A1c reduction of 0.5 – 2.0% • In development: LA exenatide, liraglutide • DPP-4 Inhibitors: sitagliptin (Januvia) • Prevents degradation of endogenous GLP-1 • Oral monotherapy and in combination • Weight-neutral: A1c reduction of 0.5 – 1% • In development: vildagliptin

  24. Optimal Use of Oral agents • Early combination therapy! • Generic metformin: inexpensive, long safety record (>50 yrs), reduced total mortality and CV events in UKPDS. Push to ≥2 grams per day, continue with insulin • Sulfonylureas: use glimepiride or glipizide (both are generic) preferentially • TZDs: contraindicated in heart failure, fluid retention esp. when combined with insulin, recent controversy and warning re: coronary artery disease • Bile-acid Sequestrant Colesevelam (Welchol): only approved Rx for both hyperlipidemia and diabetes

  25. Approach to Management of Hyperglycemia in Type 2 Diabetes:Algorithm for the Initiation and Adjustment of Therapy Joint Consensus Statement from ADA and EASD Diabetes Care, October 2008

  26. The Sugar DebatesRelationship between Glucose and Cardiovascular Disease • Does hyperglycemia predispose to macrovascular complications? • Does glucose control help to prevent or reduce cardiovascular events?

  27. Pathophysiologic and Epidemiologic DataRelationship between A1c and CVD/all-cause mortality is continuous, significant, and independent of classical risk factors, even in persons without known diabetes EPIC-NORFOLK StudyEach 1% increase in A1c above 5% was associated with a 21% increase in CV events. Ann Intern Med, Sept 2004 Harvard School of Public Health Study on Global CVD mortality: 21% of IHD and stroke deaths attributable to glucose above 90 mg/dl worldwide. Danaei et al, Lancet, Nov 2006 HUNT study20 year f/u of newly diagnosed diabetes. 20% increase in IHD mortality per 1% increment in A1c. Eur Heart J, Feb 2009

  28. “Metabolic Memory” “Legacy Effect”Continued reduction of risk from previous good control DCCT-EDIC Study – type 1 diabetesNew Engl J Med, December 2005 UKPDS 10-year follow up – type 2 diabetesNew Engl J Med, October 2008

  29. Summary of Recent Trials of Intensive Glycemic Control and Cardiovascular Disease

  30. Early vs. Late Glucose Control in Type 2 Diabetes It pays to be aggressive early in the disease! • Good glucose control early in the disease when atherosclerotic complications have not yet developed, and • Co-morbid risk factors are better addressed and easily managed …is likely to be beneficial in the long-term (primary and secondary intervention)

  31. Early vs. Late Glucose Control in Type 2 Diabetes Beware of overly-aggressive, intensive therapy in older patients with long-standing diabetes after years of poor control… • when underlying vascular problems have manifested, and • autonomic neuropathy, defective glucose counter-regulation, and hypoglycemia unawareness have supervened ….can be harmful and does not add much beyond management of other traditional risk factors (too much, too late). Higher A1c’s have to be accepted!

  32. No “One Size Fits All” • More research before we impose complex glucose control interventions that overwhelm the patients’ capacity to cope medically, psychologically, and financially • Treatment burden, cost, and harm of serious hypoglycemia, with uncertain benefits in some patients • Hba1c as a performance model (>8% as indicator of inadequate care

  33. Multifactorial therapy to reduce macrovascular risk: Steno-2 TrialDebunking the “gluco-centric” viewNew Engl J Med,2003, 2008 Multifactorial intervention aimed at multiple risk factors, behavior modification and pharmacologic therapy in type 2 diabetes: • hyperglycemia • hypertension • diabetic dyslipidemia • microalbuminuria / use of ACE-inhibitors • aspirin A 53% reduction in all cardiovascular endpoints and microvascular complications compared with conventional therapy

  34. Management of CAD in people with Diabetes; the BARI 2D study New Engl J Med June 2009 • Previous trials (BARI and meta-analyses) had shown survival benefit with CABG that persisted at 10 yrs • BARI 2D: international multicenter trial of 2368 patients with • both diabetes and CAD; 2 x 2 factorial design • No difference in primary end-point (death) with prompt • revascularization (CABG or PCI) vs. medical therapy • CABG pts had fewer cardiac events (nonfatal MI) • For most patients with less severe CAD, optimal medical • therapy rather than any intervention is an excellent 1st-line • strategy • When revascularization is indicated, bypass is the • preferred approach

  35. 2009 American Diabetes Association (ADA) Recommendations for Adults with Diabetes: Importance of Multi-factorial Therapy Diabetes Care,January 2009 Hemoglobin A1c < 7.0% * In Pregnancy < 6.5% Pre-meal plasma glucose 90-130 mg/dl Postprandial plasma glucose < 180 mg/ml Blood Pressure < 130/80 mmHg In nephropathy< 125/75 mmHg LDL < 100 mg/dl Patients above age 40 years: use statin therapy to achieve LDL reduction of 30-40% In overt CVD LDL goal of <70 using high-dose statins “is an option” HDL > 40 mg/dl Triglycerides < 150 mg/dl  -*AACE and EASD <6.5% -Goals should be individualized. Less intensive glycemic targets may be indicated if there is frequent or severe hypoglycemia

  36. Patient-Centered Care:The Team Approach • Partner with the patient: do not scold or scare! • A mutually respectful and trusting patient-provider relationship • Use and collaborate with diabetes education programs: team management! • “Refresher Courses” are often necessary • Frequent communication is key education monitoring communication early insulin multifactorial therapy

  37. Glucose Control in the Hospital, Inpatient Outcomes, and Cost of CareA challenge and an opportunity to favorably impact patient care • Open-heart surgery – Portland Diabetic Project 1987-2005 • Acute coronary events – DIGAMI 1 1995-99 and DIGAMI 2 Eur Heart J 2005 • Surgical ICU – Leuven trial 1 N Engl J Med 2001 • Medical ICU – Leuven trial 2 N Engl J Med 2006

  38. The Sugar DebatesWhat are the Optimal Glucose Targets in Hospitalized patients? • Controversial – experts divided into various camps • Labor-intensive, risk of hypoglycemia Inzucchi S: New Engl J Med, 2006

  39. Intensive versus Conventional Glucose Control in Critically Ill PatientsThe NICE-SUGAR Study Investigators , New Engl J Med, March 2009 • Multicenter, international study of 6104 ICU patients. IV insulin used to achieve a BG target of 81 to 108 (115) in the intensive group and 144 to 180 (144) in the conventional group. • 3% increase in primary end point, death at 90 days (27.5%, vs. 24.9%, a 10% higher relative mortality). A significantly higher rate of severe hypoglycemia in the intensive-control group (6.8% vs. 0.5%).

  40. Optimal Glucose Targets in Hospital Patients:The American Diabetes Association-American College of Endocrinology Consensus Statement based on the results of NICE-SUGAR Diabetes Care,May 2009 Critically ill patients • Use IV insulin in the majority of patients in the ICU setting • A starting threshold of no higher than 180 mg/dL • Maintain glucose levels between 140 and 180 mg/dL • Greater benefit may be realized at the lower end of this range • Targets less than 110 mg/dL are NOTrecommended Noncritically ill patients • Recommendations are based on “clinical experience and judgment” • Premeal glucose targets should generally be <140 mg/dL • Random glucose values <180 mg/dL Protocol Implementation: a multidisciplinary effort

  41. Take–Home Messages • Minimally-invasive, REAL-TIME glucose monitoring • eAG, and A1c for diagnosis of diabetes • “Pre-diabetes”, metabolic syndrome, genetics of diabetes • Individualize outpatient glucose targets based on type of patient and risk-benefit ratio. General A1c goal is <7% • Multifactorial therapy to reduce CVD and mortality early in the disease • Medical therapy as good as revascularization • Early use of metformin and combination oral agents • Incretin-based therapies • Intensive insulin therapy, basal-bolus, and “smart pumps” • Inpatient targets: ICU 140-180, non-critical care 110-180 • Communication, education, re-education!

More Related